Developer docs
API playgroundTry for free, no card

Search company profiles

ICAgen

Full company profile

uuid00065j5

Namestring
ICAgen
Legal namestring
OmniAb, Inc.
Websiteurl
icagen.com
Company typeenum
Public
Founded yearint
1992
Descriptiontext

ICAgen is a biopharmaceutical company founded in 1992 and headquartered in Emeryville, California. According to the input data, ICAgen develops novel orally-administered small molecule drugs that modulate ion channel targets. The company operated as a small, specialized drug discovery organization with 11-50 employees and was previously listed on NASDAQ under the ticker ICFN before being delisted. Co-founder P. Kay Wagoner and CFO Mark Korb are the named leadership figures.

ICAgen's capital base was assembled through a series of equity and grant financings rather than commercial product sales, totaling roughly $21M across disclosed rounds between 1997 and 2018. Key backers included Venrock (1997 founding-stage), Pfizer Venture Investments ($5M in 2009), and the Cystic Fibrosis Foundation ($11M in 2018), the latter representing both the largest single tranche and an indication of pipeline focus on cystic fibrosis-relevant ion channel targets. No product approvals, revenue figures, or commercial partnerships are disclosed in the supplied source material.

The bulk of the aggregated source content pertains to OmniAb, Inc. (a Ligand spin-off that merged with Avista Public Acquisition Corp. II), which markets an "Ion Channel and Transporter Technology" capability alongside its transgenic antibody discovery platforms. This suggests ICAgen's ion channel technology assets were ultimately integrated into the Ligand/OmniAb discovery ecosystem rather than commercialized as standalone therapeutics by ICAgen itself. Given ICAgen's delisted status and the absence of disclosed operating revenue or product approvals, the company should be assessed as a development-stage or asset-transferred entity rather than an active commercial biopharma.

Short descriptiontext

ICAgen is an Emeryville, California-based biopharmaceutical company founded in 1992 that develops orally-administered small molecule drugs modulating ion channel targets. The company, formerly NASDAQ-listed as ICFN, was funded by Venrock, Pfizer Ventures, and the Cystic Fibrosis Foundation.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersEmeryville, United States
HQ citystring
Emeryville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ion channel therapeutics, small molecule drugs, biopharmaceutical discovery, orally administered drugs, drug development partnerships
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Biopharmaceutical Drug Discovery
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Partnership and licensing revenue
TypeLicensing Royalties
Description

Revenue generated through partnership agreements with biopharmaceutical companies that access OmniAb's antibody discovery technologies and platforms. The partnership pipeline page and reference to over 100 biopharma partners suggest a licensing/royalty and collaborative discovery model typical of platform companies serving pharma.

omniab.com
2Discovery and professional services
TypeProfessional Services
Description

Revenue from contracted antibody discovery services, screening runs, and custom research engagements delivered to pharma partners using OmniAb's transgenic platforms and xPloration screening.

omniab.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Personnel, Technology or R&D, Operations
Pricing details1 tier
1Quote-based partnership / licensing agreements
ModelOther
Notes

No public price list; pricing is negotiated per partnership. A Partner Access Program is referenced for xPloration use, but specific pricing is not disclosed.

omniab.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 7 records shown
1OmniRat
Description

Transgenic rat platform for generating fully human antibodies

omniab.com
+6 more records
Core offering1 text field

ICAgen is a biopharmaceutical company that develops novel, orally-administered small molecule drugs designed to modulate ion channel targets. The company focuses on ion channel drug discovery and development, historically leveraging venture funding and grants (including from Pfizer Venture Investments and the Cystic Fibrosis Foundation) to advance its pipeline.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • In Silico Drug Discovery Market projected to reach USD 14.37 billion by 2034 (from USD 2.96 billion in 2024) at a 17.1% CAGR, indicating the size of the opportunity relevant to OmniAb's in silico capabilities.
+1 more record
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Ligand historically owned and operated the OmniAb business and announced plans to spin-off OmniAb through a merger with Avista Public Acquisition Corp. II. News releases highlight Ligand-originated milestones such as Janssen's EC approval for Tecvayli.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Janssen is referenced as a partner whose therapeutic (Tecvayli / teclistamab) received European Commission approval for relapsed or refractory multiple myeloma, indicating Janssen is part of the OmniAb/Ligand antibody discovery partnership pipeline.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Genentech is a major biopharmaceutical incumbent with historical interest in ion channel biology. Comparable as a broad biopharma that could partner with or acquire specialist ion channel companies like ICAgen.

TypeBroad incumbent
Description

Vertex is the dominant commercial player in cystic fibrosis therapeutics (Trikafta/Kaftrio). Directly comparable because ICAgen's CF Foundation-backed program competes in the same disease area, and Vertex represents both a potential partner and acquirer of CF ion channel assets.

TypeBroad incumbent
Description

AbbVie is a large specialty biopharma that has historically acquired and developed small-molecule assets in CNS and rare diseases. Comparable as a potential acquirer of an ion channel platform of the type ICAgen operates.

TypeBroad incumbent
Description

Pfizer is both a historical investor in ICAgen (Pfizer Venture Investments led the 2009 round) and a major biopharma developing ion-channel-targeted therapies. Comparable as both a strategic capital source and a potential acquirer of ion channel small-molecule assets.

TypeEmerging player
Description

ProQR develops RNA therapies for severe genetic diseases including cystic fibrosis. Comparable because it pursues novel CF therapeutics from a similar emerging-stage base, representing an overlapping disease-area competitor and potential strategic partner.

TypeOthers
Description

Ligand historically owned and operated the OmniAb antibody platform (which the input data references extensively). Ligand is comparable as a royalty/monetization-focused biopharma that licenses platform technologies to large pharma — a business model that could be analogous to a future ICAgen monetization strategy.

TypeDirect peer
Description

Xenon is a clinical-stage biopharma specializing in ion channel modulators for epilepsy and other neurological disorders. Most directly comparable as a similarly-sized specialist in ion channel-targeted small molecule drug development.

TypeBroad incumbent
Description

BioMarin has a meaningful CF franchise (e.g., inhaled therapies) and develops specialty small-molecule therapeutics for rare diseases. Comparable because it overlaps in CF and in the broader small-molecule rare-disease space where ICAgen operates.

TypeEmerging player
Description

Parion Sciences developed small-molecule ion channel modulators for pulmonary and ocular surface indications. Comparable as a similarly-sized specialist in ion channel pharmacology with overlapping respiratory/disease focus.

TypeEmerging player
Description

SiteOne is an emerging biopharma developing selective ion channel modulators for pain and other indications. Comparable as a similarly-positioned specialist in ion channel-targeted small molecules.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature12 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ICAgen

Biopharmaceutical Drug Discoveryicagen.com

ICAgen is an Emeryville, California-based biopharmaceutical company founded in 1992 that develops orally-administered small molecule drugs modulating ion channel targets. The company, formerly NASDAQ-listed as ICFN, was funded by Venrock, Pfizer Ventures, and the Cystic Fibrosis Foundation.

What ICAgen does

ICAgen is a biopharmaceutical company founded in 1992 and headquartered in Emeryville, California. According to the input data, ICAgen develops novel orally-administered small molecule drugs that modulate ion channel targets. The company operated as a small, specialized drug discovery organization with 11-50 employees and was previously listed on NASDAQ under the ticker ICFN before being delisted. Co-founder P. Kay Wagoner and CFO Mark Korb are the named leadership figures.

ICAgen's capital base was assembled through a series of equity and grant financings rather than commercial product sales, totaling roughly $21M across disclosed rounds between 1997 and 2018. Key backers included Venrock (1997 founding-stage), Pfizer Venture Investments ($5M in 2009), and the Cystic Fibrosis Foundation ($11M in 2018), the latter representing both the largest single tranche and an indication of pipeline focus on cystic fibrosis-relevant ion channel targets. No product approvals, revenue figures, or commercial partnerships are disclosed in the supplied source material.

The bulk of the aggregated source content pertains to OmniAb, Inc. (a Ligand spin-off that merged with Avista Public Acquisition Corp. II), which markets an "Ion Channel and Transporter Technology" capability alongside its transgenic antibody discovery platforms. This suggests ICAgen's ion channel technology assets were ultimately integrated into the Ligand/OmniAb discovery ecosystem rather than commercialized as standalone therapeutics by ICAgen itself. Given ICAgen's delisted status and the absence of disclosed operating revenue or product approvals, the company should be assessed as a development-stage or asset-transferred entity rather than an active commercial biopharma.

ICAgen firmographics

Firmographics
Name
ICAgen
Legal name
OmniAb, Inc.
Website
https://icagen.com
Company type
Public
Founded year
1992
Operating status
Operating
Headcount range
11–50 employees
Short description
ICAgen is an Emeryville, California-based biopharmaceutical company founded in 1992 that develops orally-administered small molecule drugs modulating ion channel targets. The company, formerly NASDAQ-listed as ICFN, was funded by Venrock, Pfizer Ventures, and the Cystic Fibrosis Foundation.
Ownership category
akta.pro rank

Where ICAgen is headquartered

Location

Headquarters

HQ city
Emeryville
HQ country
United States
HQ region
North America

Offices1 record

Markets served

ICAgen business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations

Revenue model

  1. Partnership and licensing revenue: Revenue generated through partnership agreements with biopharmaceutical companies that access OmniAb's antibody discovery technologies and platforms. The partnership pipeline page and reference to over 100 biopharma partners suggest a licensing/royalty and collaborative discovery model typical of platform companies serving pharma.
  2. Discovery and professional services: Revenue from contracted antibody discovery services, screening runs, and custom research engagements delivered to pharma partners using OmniAb's transgenic platforms and xPloration screening.

Pricing tiers

ModelBillingPrice
Other—Quote-based partnership / licensing agreements

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

ICAgen product offering

Product offering

Core offering

ICAgen is a biopharmaceutical company that develops novel, orally-administered small molecule drugs designed to modulate ion channel targets. The company focuses on ion channel drug discovery and development, historically leveraging venture funding and grants (including from Pfizer Venture Investments and the Cystic Fibrosis Foundation) to advance its pipeline.

Differentiator

Problem solved

Functional benefit

Brands

  • OmniRat: Transgenic rat platform for generating fully human antibodies
  • OmniMouse
  • OmniChicken
  • Omni*dAb*
  • OmniUltra
  • OmniTaur
  • xPloration

Quantifiable outcome

  • In Silico Drug Discovery Market projected to reach USD 14.37 billion by 2034 (from USD 2.96 billion in 2024) at a 17.1% CAGR, indicating the size of the opportunity relevant to OmniAb's in silico capabilities.
  • +1 more outcomes

Companies that use ICAgen

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles1 record

ICAgen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature12 records

ICAgen partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered flagship and core.

  • Ligand PharmaceuticalsflagshipStrategic or Co-development PartnerLigand historically owned and operated the OmniAb business and announced plans to spin-off OmniAb through a merger with Avista Public Acquisition Corp. II. News releases highlight Ligand-originated milestones such as Janssen's EC approval for Tecvayli.
  • Janssen (Johnson & Johnson)coreStrategic or Co-development PartnerJanssen is referenced as a partner whose therapeutic (Tecvayli / teclistamab) received European Commission approval for relapsed or refractory multiple myeloma, indicating Janssen is part of the OmniAb/Ligand antibody discovery partnership pipeline.

Scale indicators4 records

Recent moves5 records

Expansion highlights2 records

ICAgen competitors and assessment

Company assessment

Broad incumbents

  • Genentech (Roche): Genentech is a major biopharmaceutical incumbent with historical interest in ion channel biology. Comparable as a broad biopharma that could partner with or acquire specialist ion channel companies like ICAgen.
  • Vertex Pharmaceuticals: Vertex is the dominant commercial player in cystic fibrosis therapeutics (Trikafta/Kaftrio). Directly comparable because ICAgen's CF Foundation-backed program competes in the same disease area, and Vertex represents both a potential partner and acquirer of CF ion channel assets.
  • AbbVie: AbbVie is a large specialty biopharma that has historically acquired and developed small-molecule assets in CNS and rare diseases. Comparable as a potential acquirer of an ion channel platform of the type ICAgen operates.
  • Pfizer: Pfizer is both a historical investor in ICAgen (Pfizer Venture Investments led the 2009 round) and a major biopharma developing ion-channel-targeted therapies. Comparable as both a strategic capital source and a potential acquirer of ion channel small-molecule assets.
  • BioMarin Pharmaceutical: BioMarin has a meaningful CF franchise (e.g., inhaled therapies) and develops specialty small-molecule therapeutics for rare diseases. Comparable because it overlaps in CF and in the broader small-molecule rare-disease space where ICAgen operates.

Emerging players

  • ProQR Therapeutics: ProQR develops RNA therapies for severe genetic diseases including cystic fibrosis. Comparable because it pursues novel CF therapeutics from a similar emerging-stage base, representing an overlapping disease-area competitor and potential strategic partner.
  • Parion Sciences: Parion Sciences developed small-molecule ion channel modulators for pulmonary and ocular surface indications. Comparable as a similarly-sized specialist in ion channel pharmacology with overlapping respiratory/disease focus.
  • SiteOne Therapeutics: SiteOne is an emerging biopharma developing selective ion channel modulators for pain and other indications. Comparable as a similarly-positioned specialist in ion channel-targeted small molecules.

Others

  • Ligand Pharmaceuticals: Ligand historically owned and operated the OmniAb antibody platform (which the input data references extensively). Ligand is comparable as a royalty/monetization-focused biopharma that licenses platform technologies to large pharma — a business model that could be analogous to a future ICAgen monetization strategy.

Direct peers

  • Xenon Pharmaceuticals: Xenon is a clinical-stage biopharma specializing in ion channel modulators for epilepsy and other neurological disorders. Most directly comparable as a similarly-sized specialist in ion channel-targeted small molecule drug development.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks6 records

Key highlights5 records

Customer concentration

ICAgen social profiles

Digital presence

ICAgen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ICAgen leadership team

Management profile

Number of profiles

Profiles2 records

ICAgen funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ICAgen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ICAgen

What does ICAgen do?

ICAgen is a biopharmaceutical company that develops novel, orally-administered small molecule drugs designed to modulate ion channel targets. The company focuses on ion channel drug discovery and development, historically leveraging venture funding and grants (including from Pfizer Venture Investments and the Cystic Fibrosis Foundation) to advance its pipeline.

Is ICAgen a public or private company?

ICAgen is a public company. It is classified as venture growth investor backed and is currently operating.

When was ICAgen founded?

ICAgen was founded in 1992. It employs 11 to 50 people.

Where is ICAgen based?

ICAgen is headquartered in Emeryville, United States, in the North America region.

How does ICAgen make money?

Two revenue lines are on record. Partnership and licensing revenue is the primary driver. The others are discovery and professional services.

Who are ICAgen's main competitors?

Broad incumbents on record are Genentech (Roche), Vertex Pharmaceuticals, AbbVie, Pfizer and BioMarin Pharmaceutical. Emerging players are ProQR Therapeutics, Parion Sciences and SiteOne Therapeutics. Ligand Pharmaceuticals is listed as an others. Xenon Pharmaceuticals is listed as a direct peer.

Does ICAgen have an API?

No public API is recorded for ICAgen.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireCHICAGO REGION NAMED TOP METRO IN THE U.S. FOR BUSINESS, 10TH CONSECUTIVE YEARSite Selection named the Chicago region the top U.S. metro for corporate relocation for the tenth consecutive year. The region saw a 3.4% increase in Gross Regional Product and 26,000 new jobs in 2022, with transportation and logistics adding over 10,000 jobs.Business Wire BlogLigand and GSK Enter Global Collaboration and License Agreement Leveraging Icagen’s Discovery Technology to Target Neurological DisordersLigand Pharmaceuticals announced a collaboration and license agreement between its subsidiary Icagen and GlaxoSmithKline to develop inhibitors for neurological diseases. Ligand will receive an upfront payment of $7 million and up to $154.5 million in milestone payments, plus tiered royalties on commercialized drugs.Business Wire BlogLigand Completes Acquisition of Icagen Core Assets, Partnered Programs and Ion Channel TechnologiesLigand completed its acquisition of Icagen's core assets, including ion channel technologies and partnered programs, for $15 million in cash with additional payments tied to revenue. The deal includes a Roche collaboration with potential milestone payments up to $274 million and a CFF collaboration with up to $59 million in milestones. Ligand expects synergy with its Vernalis and OmniAb platforms.PR NewswireIcagen enters into Collaboration to Develop and Commercialize Therapy for Neurological DiseasesIcagen announced a license and collaboration agreement with Roche to develop and commercialize small molecule ion channel modulators for treating neurological disorders, incorporating Icagen's ion channel drug discovery platform. Under the terms, Roche will provide an upfront cash payment and research funding, with Icagen eligible to receive up to $274 million in development and commercial milestone payments plus royalty payments if a drug reaches commercialization. Icagen will conduct preclinical activities up to lead optimization, while Roche assumes responsibility for further development and global commercialization.PR NewswireIcagen Receives Award from the Cystic Fibrosis Foundation to Discover Transformative Therapies to Treat Cystic FibrosisIcagen, Inc. announced it received an award from the Cystic Fibrosis Foundation to discover therapeutics for cystic fibrosis patients with nonsense mutations, who currently have no therapies addressing the underlying cause of their disease. The foundation has committed up to $11 million to support a multi-year drug discovery initiative involving screening over 2 million compounds and using Icagen's in silico platform to analyze an additional 10 million virtual molecular structures. The collaboration aims to develop transformative therapies that could significantly improve quality of life and lifespan for affected patients.PR NewswireIcagen Announces Collaboration With Bayer To Develop Novel XRpro® AssaysIcagen announced a collaboration with Bayer to develop novel XRpro® assays designed to support Bayer's early discovery programs in transporter targets. This two-year project aims to utilize Icagen's proprietary X-ray fluorescence technology to overcome challenges in high-throughput screening for non-electrogenic transporters.PR NewswireIcagen Acquires Nanion's SyncroPatch384 High-Throughput Electrophysiology PlatformIcagen, Inc. has purchased a SyncroPatch384 high-throughput electrophysiology instrument from Nanion and entered into a collaboration agreement to develop ion channel assays for the platform, with delivery completed in May 2016. Icagen has already established assays for two different gene families and plans to continuously expand assay panels across specific gene families and diversity panels for safety screening. The partnership aims to combine Icagen's ion channel drug discovery expertise and cell line inventory with Nanion's technology to position Icagen as the preferred provider in the ion channel drug discovery space.PR NewswireAptuit e Icagen acuerdan una alianza estratégicaAptuit LLC and Icagen, Inc. have announced a strategic alliance to provide drug discovery clients access to ion channel and transporter technologies. This partnership aims to offer fully integrated solutions for drug development, leveraging Aptuit's expertise to enhance Icagen's capabilities in advancing drug candidates efficiently.PR NewswireAptuit and Icagen Agree to Strategic AllianceAptuit LLC and Icagen, Inc. announced a strategic alliance to combine their expertise in drug discovery, providing customers with access to integrated ion channel and transporter technologies. The partnership aims to offer best-in-class solutions from gene to high-quality candidates, leveraging Aptuit's medicinal chemistry capabilities and Icagen's proprietary XRpro® technology platform.PR NewswireAptuit und Icagen vereinbaren strategische AllianzAptuit LLC and Icagen, Inc. announced a strategic alliance on February 22, 2016, in Greenwich, Connecticut, to provide pharmaceutical manufacturers integrated access to ion channel and transport technology and expertise. Under the partnership, Icagen's ion channel cell lines and XRpro® X-ray fluorescence technology platform will be combined with Aptuit's integrated drug discovery services, including medicinal chemistry, in vitro DMPK, and discovery pharmacology. The alliance is expected to help both companies offer class-leading solutions for ion channel drug discovery programs and improve clients' chances of successful IND applications.